Skip to main content

Mohamed Abdel Mohsen

NIH Rank #2904
  • R01 Holder
  • Translational
  • Multi-Institutional
  • Early Career
  • Diverse Portfolio

Researcher identity and coverage

Current affiliation
Not verified in ScienceDex.NIH award organizations may differ from a researcher's employer.
NIH RePORTER identity
Profile ID 12423100Search this ID in NIH RePORTER
ScienceDex PI coverage
FY2024 through FY2026Career claims are limited to the years shown.

FY2026 award categories

  • Internal Medicine
  • Neurosciences

NIH Funding · FY2024

Linked Award Amount
$2.8M
Full award amounts, FY2024
Award Records
6
Records listing this PI
Award-Linked Rank
#2,904
By linked amount among FY2024 PIs
Earliest Year Loaded
2024
ScienceDex PI coverage

One scientist record

NIH portfolios and SHARE

This is the common ScienceDex page for Mohamed Abdel Mohsen. NIH portfolio memberships are contextual views of this scientist, while SHARE Score, S-Index, and S-Impact describe the researcher's global sharing track record.

Review metric definitions

FY2024 NIH portfolio memberships

No institute-level portfolio release is available for this scientist and fiscal year yet. Existing award history remains unchanged above.

Researcher-associated datasets

These datasets are linked to this researcher's ShareScore identity. This does not by itself prove that an NIH portfolio funded each dataset.

No compatible author-to-dataset release is published. Dataset records are unavailable, not zero.

Award-linked funding history

Linked NIH award amounts and rank by fiscal year.

FY2024 award records by amount

NIH award records listing Mohamed Abdel Mohsen as a PI. Multi-PI records show the full award amount for context.

  • 1R56AI181653-01R56
    STudy of Acute HIV for investiGating Eradication Strategies (STAGES)
    $794K
    award amount
  • 5R01AA031197-02R01
    Gut Microbiota-Mediated Inflammatory Interactions Between Alcohol Use Disorders and HIV Infection
    $718.5K
    award amount
  • 7R01AI165079-05R01
    Targeting Siglec-9/Sialoglycan Interactions to Enhance NK Functions During HIV Infection
    $408.1K
    award amount
  • 2R56AG062383-06R56
    Glycomic Modulation of Inflammaging and Immune Functions during HIV Infection
    $400K
    award amount
  • 5R01AI165079-04R01
    Targeting Siglec-9/Sialoglycan Interactions to Enhance NK Functions During HIV Infection
    $270.2K
    award amount
  • 1R21AI184073-01A1R21
    Targeting CD127-expressing tissue reservoir cells as a strategy for HIV cure
    $250.8K
    award amount

Coverage and award-record milestones

Computed from the fiscal years currently available in ScienceDex.

  1. 2024
    First NIH Award
    Northwestern University
  2. 2024
    $500K Cumulative Funding
  3. 2024
    $1M Cumulative Funding
  4. 2024
    $2M Cumulative Funding
  5. 2024
    Entered Top 50% Nationally
    Ranked #2904
  6. 2024
    Entered Top 25% Nationally
    Ranked #2904
  7. 2025
    $5M Cumulative Funding
  8. 2025
    Entered Top 10% Nationally
    Ranked #1631
  9. 2025
    Multi-Institutional Research
    Awards at 5 institutions
  10. 2025
    R01 Grant Holder